Reserve Your Atera Slot for 2026
Large-cohort spatial studies have long forced a tradeoff between transcriptome breadth, single-cell resolution, and throughput. Atera, 10x Genomics’ new in situ spatial platform, is built to remove that constraint— and Explicyte is opening a limited number of early Atera slots for 2026 (1 to 4 slides per slot), and you can reserve yours now. What Atera brings Atera measures […]
Smarter Xenium: More Biology per Slide, More Value per Sample
At the 10x Genomics Atera World Tour 2026 in Paris, Explicyte presented two case studies tackling the question every spatial biology team faces: how do we extract more biological value from FFPE tumor samples, while keeping turnaround time and cost under control? The challenge: spatial transcriptomics at scale Single-cell spatial transcriptomics is now a production […]
Inducing Tertiary Lymphoid Structures (TLS): our IHF data released in Cancer Cell (MSKCC collaboration)
New paper out in Cancer Cell ! This collaboration with the Memorial Sloan Kettering Cancer Center (MSKCC), led by David Knorr and colleagues, shows that an Fc-optimized CD40 agonist (2141-V11), delivered intratumorally, can induce tertiary lymphoid structures (TLS) and drive systemic antitumor immunity—with complete responses reported in melanoma and breast cancer. Beyond the headline result, these findings […]
Explicyte Becomes the First Immuno-Oncology CRO in Europe Equipped with the 10x Xenium Platform for Single-Cell Spatial Transcriptomics
Explicyte is proud to announce that it is the first immuno-oncology CRO in Europe equipped with the 10x Genomics Xenium platform for single-cell spatial transcriptomics. Training by the 10x Genomics team has started, marking an important milestone in the expansion of Explicyte’s spatial biology and translational immuno-oncology capabilities. A New Era for Translational Research and […]
Ultra-trail: 330 km in the Alpes to support cancer immunotherapy research
From the 8th to the 14th of September, Gregory Lebras will run 330km in the Aosta Valley, in Italy. Enlisted for the TOR330 – TOR DES GÉANTS ultra-endurance trail together with 1,100 competitors, this anesthetist nurse at the Institut Bergonié Comprehensive Cancer Center aims to raise funds to support sarcoma research. Over 7 days, he will encourage his audience to make […]
Translational Research in Cancer Immunotherapy: 5 Key Findings
Over the past 5 years, our translational team released major papers in the field of cancer immunotherapy, in collaboration with French oncologists from the Institut Bergonié and Gustave Roussy Comprehensive Cancer Centers. Here are 5 key papers to highlight what we’ve learned: In Clinical Cancer Research (2024): TROP2 is a biomarker of resistance to immune […]
TROP2: A Strong Predictor of Resistance to Immunotherapy in Lung Cancer
A new study published in Clinical Cancer Research highlights TROP2 as a strong predictor of resistance to immunotherapy, but not to chemotherapy, in patients with advanced non-small cell lung cancer. This work is the result of a collaboration between Bergonié Institute, Gustave Roussy Institute, and Explicyte. The study relied on patient samples and advanced translational […]
New Avenues in Cancer Immunotherapy: A Conversation with Pr Antoine Italiano
Following the publication of a recent article in Clinical Cancer Research, Explicyte spoke with Pr Antoine Italiano, an internationally recognized expert in early drug development, phase I oncology trials, and immuno-oncology. In this interview, Pr Italiano discusses the current challenges of cancer immunotherapy, the role of tertiary lymphoid structures in treatment response, and how patient […]
A Partnership Between Explicyte and Bergonié Institute Fuels Major Breakthroughs in Precision Immunotherapy
Bordeaux, France — June 12, 2023 — Over the past four years, Explicyte and Bergonié Institute have been conducting joint translational research programs to identify the determinants of cancer patients’ response to immunotherapy. While immunotherapy has become a major therapeutic breakthrough across several cancer indications, response rates remain limited in many patients. This highlights the […]
Back from ASCO 2023: Interview with Alban Bessede
Following the 2023 ASCO Annual Meeting, Alban Bessede, CEO of Explicyte, shares his key takeaways from this year’s edition, including major advances in antibody-drug conjugates, targeted therapies, cancer vaccines, and biomarker-driven immuno-oncology strategies. ASCO has just ended. What are your impressions of this year’s meeting? It is always a great pleasure to attend the ASCO […]